Previous 10 | Next 10 |
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor confere...
Guest speakers Include Deepak Bhatt, MD, MPH and John Fanikos, RPh, MBA Presentations from PhaseBio Leadership Team PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
Shares of PhaseBio Pharmaceuticals (PHAS) are up more than 22% in early afternoon trading.There doesn't appear to be any news or other catalyst to explain the spike.Johnson & Johnson (JNJ) and AstraZeneca (AZN) own stakes in the microcap stock which has a market cap of just $133M.A Stifel...
UTHR is progressing with its next-generation dry powder formulation, Tyvaso DPI, towards the market. It plans to file an NDA under priority review in April 2021. Tyvaso DPI and PhaseBio's Pemziviptadil are very different products. For further details see: United Therapeu...
Cardiovascular disease remains a leading cause of mortality in both the European Union and globally, with antiplatelet therapy being a core treatment to prevent cardiovascular events The lack of reversal agents for patients taking antiplatelet therapies who require urgent ...
United Therapeutics (UTHR) has announced that its Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with pulmonary arterial hypertension (“PAH”) transitioning from Tyvaso (treprostinil) inhalation solution.In a separ...
PhaseBio Pharmaceuticals (PHAS) announced data from three patients undergoing a Phase 1b/2a pilot study that evaluates the safety, pharmacokinetics, and pharmacodynamics of the company’s first-in-class, sustained-release vasoactive intestinal peptide analogue, pemziviptadil (...
New data for pemziviptadil (PB1046) support continued evaluation as a potential novel therapy of once-weekly VIP analogue for adults with pulmonary arterial hypertension; novel agent observed to be well tolerated, with no drug-related serious adverse events resulting in study drug...
PHAS has an interesting platform whose proof of concept lead asset has considerable chance of approval. If that molecule goes through, others may follow based on the ELP platform. However, the company is very low on cash. For further details see: PhaseBio: Interesting Pl...
Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients. In ...
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...